Askal Ali to Humans
This is a "connection" page, showing publications Askal Ali has written about Humans.
Connection Strength
0.413
-
Nkemdirim Okere A, Li T, Theran C, Nyasani E, Ali AA. Evaluation of factors predicting transition from prediabetes to diabetes among patients residing in underserved communities in the United States - A machine learning approach. Comput Biol Med. 2025 Mar; 187:109824.
Score: 0.041
-
Ali AA, Kulkarni A, Bhattacharjee S, Diaby V. Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework. Pharmacoeconomics. 2024 Jul; 42(Suppl 2):211-224.
Score: 0.039
-
Abegaz TM, Baljoon A, Kilanko O, Sherbeny F, Ali AA. Machine learning algorithms to predict major adverse cardiovascular events in patients with diabetes. Comput Biol Med. 2023 09; 164:107289.
Score: 0.037
-
Abegaz TM, Diaby V, Sherbeny F, Ali AA. Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA. Clin Drug Investig. 2022 Jun; 42(6):501-511.
Score: 0.034
-
Ali AA, Tawk R, Xiao H, Semykina A, Montero AJ, Moussa RK, Popoola O, Diaby V. Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2022 Jul; 22(5):735-741.
Score: 0.034
-
Diaby V, Almutairi RD, Babcock A, Moussa RK, Ali A. Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews. Expert Rev Pharmacoecon Outcomes Res. 2021 Jun; 21(3):353-364.
Score: 0.031
-
Ali AA, Tawk R, Xiao H, Campbell E, Semykina A, Montero AJ, Mogos M, Diaby V. Comparative effectiveness of radiotherapy for early-stage hormone receptor-positive breast cancer in elderly women using real-world data. Cancer Med. 2019 01; 8(1):117-127.
Score: 0.027
-
Ali AA, Xiao H, Tawk R, Campbell E, Semykina A, Montero AJ, Diaby V. Comparison of health utility weights among elderly patients receiving breast-conserving surgery plus hormonal therapy with or without radiotherapy. Curr Med Res Opin. 2017 02; 33(2):391-400.
Score: 0.023
-
Ali AA, Xiao H, Kiros GE. Health insurance and breast-conserving surgery with radiation treatment. Am J Manag Care. 2014 Jun; 20(6):502-16.
Score: 0.020
-
Zhang X, Dutton M, Liu R, Ali AA, Sherbeny F. Deep Learning-Based Survival Analysis for Receiving a Steatotic Donor Liver Versus Waiting for a Standard Liver. Transplant Proc. 2023 Dec; 55(10):2436-2443.
Score: 0.009
-
Nkemdirim Okere A, Moussa RK, Ali A, Diaby VK. Development and validation of a tool to predict high-need, high-cost patients hospitalised with ischaemic heart disease. BMJ Open. 2023 09 26; 13(9):e073485.
Score: 0.009
-
Luque JS, Kiros GE, Vargas M, Jackson DR, Matthew OO, Austin TD, Tawk R, Ali AA, Harris CM, Wallace K, Gwede CK. Association of Preventive Care Attitudes and Beliefs with Colorectal Cancer Screening History among African American Patients of Community Health Centers. J Cancer Educ. 2023 12; 38(6):1816-1824.
Score: 0.009
-
Luque JS, Matthew OO, Jackson DR, Vargas MA, Austin T, Ali A, Kiros GE, Harris CM, Tawk R, Gwede CK, Wallace K, Jean-Pierre P. Assessing the effectiveness of a community health advisor plus screen to save educational intervention on stool-based testing adherence in an African American safety net clinic population: study protocol for a randomized pragmatic trial. Trials. 2022 Feb 15; 23(1):151.
Score: 0.008
-
Diaby V, Ali A, Babcock A, Fuhr J, Braithwaite D. Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions. J Manag Care Spec Pharm. 2021 Sep; 27(9-a Suppl):S22-S29.
Score: 0.008
-
Luque JS, Vargas M, Wallace K, Matthew OO, Tawk R, Ali AA, Kiros GE, Harris CM, Gwede CK. Engaging the Community on Colorectal Cancer Screening Education: Focus Group Discussions Among African Americans. J Cancer Educ. 2022 04; 37(2):251-262.
Score: 0.008
-
Babcock A, Ali AA, Balkrishnan R, Montero A, Diaby V. Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: A Commentary. J Manag Care Spec Pharm. 2020 Jul; 26(7):826-831.
Score: 0.008
-
Diaby V, Alqhtani H, van Boemmel-Wegmann S, Wang CY, Ali AA, Balkrishnan R, Ko Y, Palacio S, de Lima Lopes G. A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. Breast. 2020 Feb; 49:141-148.
Score: 0.007
-
Xiao H, Jiang X, Chen C, Wang W, Wang CY, Ali AA, Berthe A, Moussa RK, Diaby V. Using time series analysis to forecast the health-related quality of life of post-menopausal women with non-metastatic ER+ breast cancer: A tutorial and case study. Res Social Adm Pharm. 2020 Aug; 16(8):1095-1099.
Score: 0.007
-
Diaby V, Ali AA, Williams KJ, Ezendu K, Soto-Perez-de-Celis E, Chavarri-Guerra Y, de Lima Lopes G. Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. Breast Cancer Res Treat. 2017 Dec; 166(3):951-963.
Score: 0.006
-
Diaby V, Adunlin G, Ali AA, Zeichner SB, de Lima Lopes G, Kohn CG, Montero AJ. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat. 2016 11; 160(1):187-196.
Score: 0.006
-
Diaby V, Ali AA, Adunlin G, Kohn CG, Montero AJ. Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. Curr Med Res Opin. 2016 06; 32(6):991-6.
Score: 0.006
-
Xiao H, Tan F, Adunlin G, Ali AA, Goovaerts P, Gwede CK, Huang Y. Factors associated with overall survival prostate cancer in Florida: a multilevel analysis. J Health Care Poor Underserved. 2015 Feb; 26(1):266-77.
Score: 0.005
-
Xiao H, Tan F, Goovaerts P, Adunlin G, Ali AA, Gwede CK, Huang Y. Impact of Comorbidities on Prostate Cancer Stage at Diagnosis in Florida. Am J Mens Health. 2016 07; 10(4):285-95.
Score: 0.005
-
Diaby V, Adunlin G, Ali AA, Tawk R. Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. Breast Cancer Res Treat. 2014 Aug; 146(3):669-73.
Score: 0.005
-
Xiao H, Tan F, Goovaerts P, Ali A, Adunlin G, Gwede CK, Huang Y. Multilevel Factors Associated With Overall Mortality for Men Diagnosed With Prostate Cancer in Florida. Am J Mens Health. 2014 Jul; 8(4):316-26.
Score: 0.005
-
Xiao H, Tan F, Goovaerts P, Adunlin G, Ali A, Huang Y, Gwede CK. Factors associated with time-to-treatment of prostate cancer in Florida. J Health Care Poor Underserved. 2013 Nov; 24(4 Suppl):132-46.
Score: 0.005
-
Xiao H, Tan F, Goovaerts P, Ali A, Adunlin G, Huang Y, Gwede C. Construction of a comorbidity index for prostate cancer patients linking state cancer registry with inpatient and outpatient data. J Registry Manag. 2013; 40(4):159-64.
Score: 0.004
-
Xiao H, Tan F, Goovaerts P, Adunlin G, Ali AA, Gwede CK, Huang Y. Use of treatment information from a state central cancer registry in prostate cancer research. J Registry Manag. 2013; 40(3):127-30.
Score: 0.004